$VTAE Wedbush Reiterates “Outperform” Ratin
Post# of 22757
Posted On: 03/08/2016 8:31:57 AM
$VTAE
Wedbush Reiterates “Outperform” Rating for Vitae Pharmaceuticals Inc (VTAE)
Posted by paymon on Mar 7th, 2016 // No Comments
Vitae Pharmaceuticals logoVitae Pharmaceuticals Inc (NASDAQ:VTAE)‘s stock had its “outperform” rating reiterated by equities researchers at Wedbush in a research note issued to investors on Thursday, MarketBeat Ratings reports. They currently have a $20.00 price target on the stock. Wedbush’s price target suggests a potential upside of 326.44% from the stock’s current price.
VTAE has been the topic of a number of other research reports. Piper Jaffray reaffirmed a “buy” rating and set a $23.00 target price (up previously from $18.00) on shares of Vitae Pharmaceuticals in a report on Monday, January 4th. Zacks Investment Research downgraded Vitae Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, November 10th. Wells Fargo started coverage on Vitae Pharmaceuticals in a report on Thursday, December 3rd. They issued an “outperform” rating on the stock. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $22.00 price target on shares of Vitae Pharmaceuticals in a report on Wednesday, December 30th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $21.00.
Vitae Pharmaceuticals (NASDAQ:VTAE) opened at 4.69 on Thursday. Vitae Pharmaceuticals has a one year low of $4.15 and a one year high of $18.71. The company’s 50-day moving average price is $9.53 and its 200-day moving average price is $12.14. The firm’s market cap is $102.57 million.
Vitae Pharmaceuticals (NASDAQ:VTAE) last released its earnings results on Thursday, March 3rd. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.10. The firm had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.14 million. During the same period in the prior year, the business earned ($0.40) EPS. The company’s quarterly revenue was down 42.9% on a year-over-year basis. On average, analysts anticipate that Vitae Pharmaceuticals will post ($2.21) EPS for the current year.
A number of hedge funds have bought and sold shares of the stock. Ghost Tree Capital LLC boosted its stake in Vitae Pharmaceuticals by 10.0% in the fourth quarter. Ghost Tree Capital LLC now owns 275,000 shares of the company’s stock valued at $4,978,000 after buying an additional 25,000 shares in the last quarter. Boxer Capital LLC purchased a new position in shares of Vitae Pharmaceuticals during the fourth quarter valued at about $4,530,000. D. E. Shaw & Co. Inc. boosted its position in shares of Vitae Pharmaceuticals by 68.3% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 203,462 shares of the company’s stock valued at $3,683,000 after buying an additional 82,539 shares during the period. Millennium Management LLC boosted its position in shares of Vitae Pharmaceuticals by 15.2% in the fourth quarter. Millennium Management LLC now owns 873,436 shares of the company’s stock valued at $15,809,000 after buying an additional 114,981 shares during the period. Finally, Balyasny Asset Management LLC purchased a new position in shares of Vitae Pharmaceuticals during the fourth quarter valued at about $2,096,000.
In related news, CEO Jeffrey S. Hatfield sold 22,524 shares of the firm’s stock in a transaction that occurred on Wednesday, December 23rd. The stock was sold at an average price of $17.00, for a total value of $382,908.00. Following the sale, the chief executive officer now directly owns 293,897 shares in the company, valued at approximately $4,996,249. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Donald J. Hayden, Jr. sold 16,130 shares of the firm’s stock in a transaction that occurred on Tuesday, December 29th. The shares were sold at an average price of $18.00, for a total value of $290,340.00. The disclosure for this sale can be found here.
Vitae Pharmaceuticals, Inc is a clinical stage biotechnology company focused on discovering and developing small molecule drugs for diseases where there are unmet medical needs. The Company is developing a portfolio of product candidates generated by Contour, its structure-based drug discovery platform.
12 Month Chart for NASDAQ:VTAE
Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).
Receive News & Ratings for Vitae Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitae Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
Wedbush Reiterates “Outperform” Rating for Vitae Pharmaceuticals Inc (VTAE)
Posted by paymon on Mar 7th, 2016 // No Comments
Vitae Pharmaceuticals logoVitae Pharmaceuticals Inc (NASDAQ:VTAE)‘s stock had its “outperform” rating reiterated by equities researchers at Wedbush in a research note issued to investors on Thursday, MarketBeat Ratings reports. They currently have a $20.00 price target on the stock. Wedbush’s price target suggests a potential upside of 326.44% from the stock’s current price.
VTAE has been the topic of a number of other research reports. Piper Jaffray reaffirmed a “buy” rating and set a $23.00 target price (up previously from $18.00) on shares of Vitae Pharmaceuticals in a report on Monday, January 4th. Zacks Investment Research downgraded Vitae Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, November 10th. Wells Fargo started coverage on Vitae Pharmaceuticals in a report on Thursday, December 3rd. They issued an “outperform” rating on the stock. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $22.00 price target on shares of Vitae Pharmaceuticals in a report on Wednesday, December 30th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $21.00.
Vitae Pharmaceuticals (NASDAQ:VTAE) opened at 4.69 on Thursday. Vitae Pharmaceuticals has a one year low of $4.15 and a one year high of $18.71. The company’s 50-day moving average price is $9.53 and its 200-day moving average price is $12.14. The firm’s market cap is $102.57 million.
Vitae Pharmaceuticals (NASDAQ:VTAE) last released its earnings results on Thursday, March 3rd. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.10. The firm had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.14 million. During the same period in the prior year, the business earned ($0.40) EPS. The company’s quarterly revenue was down 42.9% on a year-over-year basis. On average, analysts anticipate that Vitae Pharmaceuticals will post ($2.21) EPS for the current year.
A number of hedge funds have bought and sold shares of the stock. Ghost Tree Capital LLC boosted its stake in Vitae Pharmaceuticals by 10.0% in the fourth quarter. Ghost Tree Capital LLC now owns 275,000 shares of the company’s stock valued at $4,978,000 after buying an additional 25,000 shares in the last quarter. Boxer Capital LLC purchased a new position in shares of Vitae Pharmaceuticals during the fourth quarter valued at about $4,530,000. D. E. Shaw & Co. Inc. boosted its position in shares of Vitae Pharmaceuticals by 68.3% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 203,462 shares of the company’s stock valued at $3,683,000 after buying an additional 82,539 shares during the period. Millennium Management LLC boosted its position in shares of Vitae Pharmaceuticals by 15.2% in the fourth quarter. Millennium Management LLC now owns 873,436 shares of the company’s stock valued at $15,809,000 after buying an additional 114,981 shares during the period. Finally, Balyasny Asset Management LLC purchased a new position in shares of Vitae Pharmaceuticals during the fourth quarter valued at about $2,096,000.
In related news, CEO Jeffrey S. Hatfield sold 22,524 shares of the firm’s stock in a transaction that occurred on Wednesday, December 23rd. The stock was sold at an average price of $17.00, for a total value of $382,908.00. Following the sale, the chief executive officer now directly owns 293,897 shares in the company, valued at approximately $4,996,249. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Donald J. Hayden, Jr. sold 16,130 shares of the firm’s stock in a transaction that occurred on Tuesday, December 29th. The shares were sold at an average price of $18.00, for a total value of $290,340.00. The disclosure for this sale can be found here.
Vitae Pharmaceuticals, Inc is a clinical stage biotechnology company focused on discovering and developing small molecule drugs for diseases where there are unmet medical needs. The Company is developing a portfolio of product candidates generated by Contour, its structure-based drug discovery platform.
12 Month Chart for NASDAQ:VTAE
Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).
Receive News & Ratings for Vitae Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitae Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼